Display options
Cite
Tani H, Morikawa S, Matsuura Y. Development and Applications of VSV Vectors Based on Cell Tropism. Front Microbiol. 2012;2:272doi: 10.3389/fmicb.2011.00272.
Tani, H., Morikawa, S., & Matsuura, Y. (2011). Development and Applications of VSV Vectors Based on Cell Tropism. Frontiers in microbiology, 2272. https://doi.org/10.3389/fmicb.2011.00272
Tani, Hideki, et al. "Development and Applications of VSV Vectors Based on Cell Tropism." Frontiers in microbiology vol. 2 (2011): 272. doi: https://doi.org/10.3389/fmicb.2011.00272
Tani H, Morikawa S, Matsuura Y. Development and Applications of VSV Vectors Based on Cell Tropism. Front Microbiol. 2012 Jan 18;2:272. doi: 10.3389/fmicb.2011.00272. eCollection 2011. PMID: 22279443; PMCID: PMC3260743.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2012 Jan 18;2:272. doi: 10.3389/fmicb.2011.00272. eCollection 2011.

Development and Applications of VSV Vectors Based on Cell Tropism.

Frontiers in microbiology

Hideki Tani, Shigeru Morikawa, Yoshiharu Matsuura

Affiliations

  1. Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, Musashimurayama Tokyo, Japan.

PMID: 22279443 PMCID: PMC3260743 DOI: 10.3389/fmicb.2011.00272

Abstract

Viral vectors have been available in various fields such as medical and biological research or gene therapy applications. Targeting vectors pseudotyped with distinct viral envelope proteins that influence cell tropism and transfection efficiency are useful tools not only for examining entry mechanisms or cell tropisms but also for vaccine vector development. Vesicular stomatitis virus (VSV) is an excellent candidate for development as a pseudotype vector. A recombinant VSV lacking its own envelope (G) gene has been used to produce a pseudotype or recombinant VSV possessing the envelope proteins of heterologous viruses. These viruses possess a reporter gene instead of a VSV G gene in their genome, and therefore it is easy to evaluate their infectivity in the study of viral entry, including identification of viral receptors. Furthermore, advantage can be taken of a property of the pseudotype VSV, which is competence for single-round infection, in handling many different viruses that are either difficult to amplify in cultured cells or animals or that require specialized containment facilities. Here we describe procedures for producing pseudotype or recombinant VSVs and a few of the more prominent examples from envelope viruses, such as hepatitis C virus, Japanese encephalitis virus, baculovirus, and hemorrhagic fever viruses.

Keywords: entry mechanism; pseudotype; recombinant; vesicular stomatitis virus

References

  1. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11359-65 - PubMed
  2. J Virol. 1998 Jun;72(6):4704-11 - PubMed
  3. J Gen Virol. 1997 Oct;78 ( Pt 10):2657-64 - PubMed
  4. J Virol. 2000 May;74(9):4139-45 - PubMed
  5. Gene Ther. 1998 Apr;5(4):531-6 - PubMed
  6. Cell. 1977 Jul;11(3):505-11 - PubMed
  7. J Exp Med. 2003 Mar 3;197(5):633-42 - PubMed
  8. J Virol. 2011 Jun;85(11):5679-84 - PubMed
  9. J Virol Methods. 2010 Nov;169(2):365-74 - PubMed
  10. J Virol. 2010 Mar;84(6):2798-807 - PubMed
  11. J Virol. 2003 Sep;77(18):9799-808 - PubMed
  12. Virology. 2001 Jan 5;279(1):343-53 - PubMed
  13. J Virol. 2008 Nov;82(21):10684-92 - PubMed
  14. J Virol. 2007 Aug;81(16):8601-12 - PubMed
  15. Vaccine. 2009 Feb 5;27(6):893-903 - PubMed
  16. J Virol. 2001 Aug;75(15):7078-85 - PubMed
  17. J Virol. 2005 Oct;79(19):12566-74 - PubMed
  18. J Virol. 2010 Aug;84(15):7513-22 - PubMed
  19. Gene Ther. 2004 Feb;11(3):266-75 - PubMed
  20. Curr Top Microbiol Immunol. 2000;242:43-54 - PubMed
  21. J Virol. 2004 May;78(10):5458-65 - PubMed
  22. Biochem Biophys Res Commun. 2008 Jul 4;371(3):446-50 - PubMed
  23. Science. 1999 Jul 2;285(5424):110-3 - PubMed
  24. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14764-9 - PubMed
  25. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6 - PubMed
  26. J Virol. 2008 Jul;82(13):6470-80 - PubMed
  27. J Virol Methods. 2009 Sep;160(1-2):7-13 - PubMed
  28. Virology. 2009 Mar 1;385(1):47-57 - PubMed
  29. Virus Res. 2011 Sep;160(1-2):404-8 - PubMed
  30. Nature. 1974 Dec 20;252(5485):743-5 - PubMed
  31. J Virol. 1999 Aug;73(8):6937-45 - PubMed
  32. Virology. 2001 Aug 1;286(2):263-75 - PubMed
  33. Hum Gene Ther. 2003 Jan 1;14(1):67-77 - PubMed
  34. J Gen Virol. 2001 Apr;82(Pt 4):821-830 - PubMed
  35. Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10099-103 - PubMed
  36. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2348-52 - PubMed
  37. J Virol. 2005 Nov;79(21):13231-8 - PubMed
  38. J Virol. 2005 Oct;79(20):12818-27 - PubMed
  39. J Med Virol. 2006 Dec;78(12):1509-12 - PubMed
  40. J Virol. 2002 May;76(10):4901-11 - PubMed
  41. Blood. 2005 Sep 1;106(5):1552-8 - PubMed
  42. J Gen Virol. 2005 Aug;86(Pt 8):2269-2274 - PubMed
  43. Virology. 2007 Dec 5;369(1):1-11 - PubMed
  44. J Virol. 2006 Jul;80(14):6964-72 - PubMed
  45. J Virol. 2004 Mar;78(6):3196-9 - PubMed
  46. Hepatology. 1999 Sep;30(3):595-601 - PubMed
  47. Virol J. 2007 Sep 06;4:83 - PubMed
  48. J Virol. 2011 Mar;85(6):2942-52 - PubMed
  49. J Virol. 2001 Nov;75(22):11079-87 - PubMed
  50. J Virol. 2010 Apr;84(7):3210-9 - PubMed
  51. Virology. 2001 Jul 20;286(1):206-15 - PubMed
  52. J Virol. 2008 Jul;82(14):7034-46 - PubMed
  53. Vaccine. 2006 Apr 5;24(15):2928-34 - PubMed
  54. J Virol. 1998 May;72(5):3539-46 - PubMed
  55. Intervirology. 2007;50(2):85-92 - PubMed
  56. Clin Vaccine Immunol. 2009 Aug;16(8):1132-8 - PubMed

Publication Types